Search Result

Results for "

TNK1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Epigenetic Reader Domain (1) ERK (1) LRRK2 (2) PARP (23) Small Interfering RNA (siRNA) (3) STAT (2) Wnt (4) β-catenin (2)
By Research Areas:	Cancer (25) Inflammation/Immunology (2) Neurological Disease (2)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (3)

Inhibitors & Agonists

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147316

TP-5801	STAT	Cancer
TP-5801 is an orally active *TNK1* (non-receptor tyrosine kinase) inhibitor (IC₅₀=1.40 nM), and shows anti-tumor activity ^[1].

HY-147316A

TP-5801 TFA	STAT	Cancer
TP-5801 TFA is an orally active *TNK1* (non-receptor tyrosine kinase) inhibitor (IC₅₀=1.40 nM), and shows anti-tumor activity ^[1].

HY-14443

XMD8-92 10+ Cited Publications	ERK Epigenetic Reader Domain	Cancer
XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with K_ds of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with K_ds of 190, 600 and 890 nM, respectively. Anti-cancer activity ^[1] .

HY-15800A

CZC-25146	LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 is a potent and orally active LRRK2 inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 can be used to research Parkinson's disease and liver diseases ^[1] .

HY-RS18502

Tnk1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tnk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tnk1 Mouse Pre-designed siRNA Set A Tnk1 Mouse Pre-designed siRNA Set A

HY-RS14837

TNK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TNK1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNK1 Human Pre-designed siRNA Set A TNK1 Human Pre-designed siRNA Set A

HY-153259

TNKS1/2-IN-2	PARP	Cancer
TNKS1/2-IN-2 (Compound 21) is a potent and selective tankyrases inhibitor. TNKS1/2-IN-2 exhibits IC₅₀ values of 4 nM and 63 nM against TNK1 and TNK2 in the enzymatic assay, respectively. TNKS1/2-IN-2 inhibits proliferation of A549 and H292 cell lines with IC₅₀ values of 39.5 nM and 12.8 nM, respectively. TNKS1/2-IN-2 can be used for the research of cancer ^[1].

HY-15800

CZC-25146 hydrochloride	LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 hydrochloride prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 hydrochloride exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 hydrochloride can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 hydrochloride can be used to research Parkinson's disease and liver diseases ^[1] .

HY-12577

TNKS1/2-IN-1	PARP	Cancer
TNKS1/2-IN-1 is a potent tankyrase TNKS1/2 inhibitor with pIC₅₀s ranging from 7.1-8.2. TNKS1/2-IN-1 can be used for research of cancer, fibrosis, and other hyperproliferative diseases ^[1].

HY-146336

PARP1/2/TNKS1/2-IN-1	PARP Apoptosis	Cancer
PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual *PARP-1, PARP-2, TNKS1* and *TNKS2* inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis ^[1].

HY-RS14842

TNKS1BP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TNKS1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNKS1BP1 Human Pre-designed siRNA Set A TNKS1BP1 Human Pre-designed siRNA Set A

HY-23338

TNKS-2-IN-1	PARP	Others
TNKS-2-IN-1 (Compound 13g) is a *TNKS-2* inhibitor. TNKS-2-IN-1 inhibits TNKS-1 and TNKS-2 with IC₅₀s of 259 nM and 1100 nM ^[1].

HY-12418

Stenoparib 2 Publications Verification E7449; 2X-121	PARP	Cancer
Stenoparib (E7449) is a potent *PARP1* and PARP2 inhibitor and also inhibits *TNKS1* and *TNKS2, with IC₅₀s of 2.0, 1.0, ∼50 and ∼50 nM for PARP1, PARP2, TNKS1* and TNKS2, respectively, using ³²P-NAD ⁺ as substrate.

HY-13968

JW 55 3 Publications Verification	PARP	Cancer
JW 55 is a potent and selective β-catenin signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC₅₀s of 1.9 μM and 830 nM respectively.

HY-12438

G007-LK 5+ Cited Publications	PARP	Cancer
G007-LK is a potent and selective inhibitor of *TNKS1* and *TNKS2, with IC₅₀*s of 46 nM and 25 nM, respectively.

HY-152197

Tankyrase-IN-3	PARP	Cancer
Tankyrase-IN-3 is a tankyrase 1 (TNKS1) inhibitor with an IC₅₀ value of 22 nM. Tankyrase-IN-3 can be used for the research of cancer ^[1].

HY-152198

Tankyrase-IN-4	PARP	Cancer
Tankyrase-IN-4 is a tankyrase 1 (TNKS1) inhibitor with an IC₅₀ value of 0.8 nM. Tankyrase-IN-4 can be used for the research of cancer ^[1].

HY-147245

Basroparib STP1002	PARP	Cancer
Basroparib (STP1002) is a selective, orally active inhibitor of tankyrase (TNKS1/TNKS2) with IC₅₀ of 29.94 nM and 3.68 nM for TNKS1 and TNKS2, respectively. Basroparib has an IC₅₀ of >10 μM for PARP1. Basroparib binds to TNKS, stabilizes *AXIN1/2* proteins, blocks Wnt/β-catenin signaling pathway, inhibits tumor cell proliferation and induces apoptosis, while reducing cancer stem cell properties. Basroparib can be used in colorectal cancer (CRC) studies with KRAS mutations (such as G12V/G12D) to overcome acquired resistance to MEK inhibitors. STP1002 has synergistic antitumor activity with MEK inhibitors ^[1] .

HY-U00422

K-756 2 Publications Verification	PARP	Cancer
K-756 is a direct and selective tankyrase (TNKS) inhibitor, which inhibits the ADP-ribosylation activity of *TNKS1* and *TNKS2* with IC₅₀s of 31 and 36 nM, respectively.

HY-137849

RK-582	PARP	Cancer
RK-582 is an orally active, spiroindoline-based selective inhibitor of tankyrase. The IC₅₀s of RK-582 against TNKS1/PARP5A and PARP1 are 36.1 nM and 18.168 nM, respectively. RK-582 inhibits rectal cancer COLO-320DM cells (GI50=0.23 μM) and significantly inhibits tumor growth in a COLO-320DM mouse xenograft model ^[1].

HY-12601

TNKS 22 TNKS-IN-22	PARP	Cancer
TNKS 22 (compound 22) is an orally active and selective tankyrase inhibitor. TNKS 22 inhibits *TNKS1* and *TNKS2* with IC₅₀s of 0.1 and 4.1 nM, respectively ^[1].

HY-19351

MN-64 3 Publications Verification	PARP	Cancer
MN-64 is a potent tankyrase 1 inhibitor, with IC₅₀s of 6 nM, 72 nM, 19.1 μM, and 39.4 μM for *TNKS1, TNKS*2, ARTD1 and ARTD2, respectively.

HY-153332

Tankyrase-IN-5	PARP	Cancer
Tankyrase-IN-5 (Compound 30f), an analogue of MSC2504877 (HY-123851), is a tankyrase *TNKS1* and *TNKS2* inhibitor with IC₅₀s of 2.3 nM and 7.9 nM, respectively ^[1].

HY-147886

PARP1-IN-11	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent *PARP1* inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 ^[1].

HY-126248

Tankyrase-IN-2	PARP Wnt	Cancer
Tankyrase-IN-2 (compound 5k) is a potent, selective, and orally active tankyrase inhibitor (IC₅₀s of 10, 7, and 710 nM for TNKS1, TNKS2 as well as PARP1, respectively). Tankyrase-IN-2 has favorable physicochemical profile and pharmacokinetic properties modulating Wnt pathway activity in a colorectal xenograft model ^[1].

HY-108516

TC-E 5001	Wnt PARP	Cancer
TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with K_ds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC₅₀s of 0.709 μM and 0.215 μM, respectively ^[1] .

HY-12975

AZ6102 1 Publications Verification	PARP	Cancer
AZ6102 is a potent dual *TNKS1* and *TNKS2* inhibitor, with IC₅₀s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC₅₀s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.

HY-15147

XAV-939 Maximum Cited Publications 142 Publications Verification	β-catenin PARP	Cancer
XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC₅₀ values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation ^[1] .

HY-145267

OM-153	PARP Wnt	Cancer
OM-153 is a potent and orally active tankyrase inhibitor with IC₅₀s of 13 nM and 2 nM for tankyrase 1 and tankyrase 2 (TNKS1/2), respectively. OM-153 inhibits luciferase-based Wnt/β-catenin signaling reporter activity with an IC₅₀ value of 0.63 nM. OM-153 shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM ^[1] .

HY-168925

EXQ-2d	Wnt PARP β-catenin	Cancer
EXQ-2d is the inhibitor for tankyrase and inhibits *TNKS1* and *TNKS2* with an IC₅₀ of 48.8 nM and 13.8 nM (pIC₅₀=7.31 and 7.86). EXQ-2d inhibits WNT/β-catenin signaling pathway with IC₅₀ of 515 nM. EXQ-2d exhibits anti-proliferative activity in cancer cells COLO 320DM and RKO with GI₅₀ of 4.9 μM and 77 μM ^[1].

HY-100847

AZ0108	PARP	Cancer
AZ0108 is an inhibitor for poly ADP-ribose polymerase (PARP), which inhibits PARP1, PARP2, PARP3, PARP6, TNKS1, TNKS2, with IC₅₀s of <0.03, <0.03, 2.8, 0.083, 3.2, >3 μM, respectively. AZ0108 prevents centrosome clustering with an EC₅₀ of 0.053 μM, and exhibits cytotoxicity in cell OCI-LY-19 with GI₅₀ of 0.017 μM. AZ0108 exhibits good in vivo pharmacokinetic characters in rat/mouse models ^[1].

Tnk1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Tnk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNK1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
TNK1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNKS1BP1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
TNKS1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: